Vanda Pharmaceuticals Inc. (VNDA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VNDA SEC filings page.
Vanda Pharmaceuticals Inc. (VNDA) reported $215.7M in revenue over the twelve months to Jun 30, 2026, up 6.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue returned to growth in FY2025, but sharply higher operating spending turned a high-gross-margin business into a large loss.
Gross margin remained roughly 94% in both FY2024 and FY2025 while operating margin collapsed to-69.9% , showing the deterioration occurred after production rather than in product-level profitability. SG&A and R&D combined increased from$220.7M to$347.2M , overwhelming the gross profit generated by sales.
Cash conversion deteriorated alongside earnings: operating cash flow changed from positive in FY2023 to negative in FY2025, so the reported loss was accompanied by an actual operating cash drain. FY2025 free cash flow of
The liquidity cushion narrowed: the current ratio fell from 4.9x in FY2023 to 2.4x in FY2025, reflecting faster growth in short-term obligations than readily available current assets. Debt-to-equity reached 0.5x, while reported liquidity equaled 28.9 months of the latest annual operating outflow.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Vanda Pharmaceuticals Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Vanda Pharmaceuticals Inc. has an operating margin of -70.0%, meaning the company loses $70 on every $100 of revenue. This results in a profitability score of 11/100. This is down from -20.5% the prior year.
Vanda Pharmaceuticals Inc.'s revenue grew 8.7% year-over-year to $216.1M, a solid pace of expansion. This earns a growth score of 53/100.
Vanda Pharmaceuticals Inc. has a moderate D/E ratio of 0.49. This balance of debt and equity financing earns a leverage score of 61/100.
With a current ratio of 2.39, Vanda Pharmaceuticals Inc. holds $2.39 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 68/100.
Vanda Pharmaceuticals Inc.'s operations used $109.4M of cash, and capex of $998K added to the outflow, for a free cash flow shortfall of $110.4M. This results in a cash flow score of 7/100.
Vanda Pharmaceuticals Inc. posts a -67.4% return on equity (ROE), meaning it loses $67 for every $100 of shareholders' equity. This results in a returns score of 12/100. This is down from -3.5% the prior year.
Vanda Pharmaceuticals Inc. scores -0.17, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($279.9M) relative to total liabilities ($161.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Vanda Pharmaceuticals Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Vanda Pharmaceuticals Inc. reported a net loss of $220.5M while operations used $109.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Vanda Pharmaceuticals Inc. generated $50.5M in revenue in Q2 2026. This represents a decrease of 3.9% from the same quarter a year earlier. Against the prior quarter it is down 2.3%.
Vanda Pharmaceuticals Inc.'s EBITDA was -$61.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 68.7% from the same quarter a year earlier. Against the prior quarter it is down 28.3%.
Vanda Pharmaceuticals Inc. reported -$62.5M in net income in Q2 2026. This represents a decrease of 129.8% from the same quarter a year earlier. Against the prior quarter it is down 28.7%.
Vanda Pharmaceuticals Inc. earned -$1.04 per diluted share (EPS) in Q2 2026. This represents a decrease of 126.1% from the same quarter a year earlier. Against the prior quarter it is down 26.8%.
Cash & Balance Sheet
Vanda Pharmaceuticals Inc. recorded an outflow of $31.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 101.0% from the same quarter a year earlier. Against the prior quarter it is up 38.0%.
Vanda Pharmaceuticals Inc. held $55.9M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Vanda Pharmaceuticals Inc.'s gross margin was 93.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.
Vanda Pharmaceuticals Inc.'s ROE was -28.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 22.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.1 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Vanda Pharmaceuticals Inc. invested $37.0M in research and development in Q2 2026. This represents an increase of 68.0% from the same quarter a year earlier. Against the prior quarter it is up 30.0%.
Vanda Pharmaceuticals Inc. invested $190K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 36.5% from the same quarter a year earlier. Against the prior quarter it is down 14.0%.
Not reported for Q2 2026.
VNDA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.5M-3.9% | $51.7M+3.4% | $57.2M+7.6% | $56.3M+18.1% | $52.6M+4.2% | $50.0M+5.4% | $53.2M+17.5% | $47.7M+22.8% |
| Cost of Revenue | $3.6M+30.1% | $3.2M-10.3% | $3.8M+48.0% | $3.0M+15.8% | $2.7M+0.1% | $3.5M+2.4% | $2.6M-25.1% | $2.6M-16.7% |
| Gross Profit | $47.0M-5.8% | $48.6M+4.4% | $53.4M+5.5% | $53.3M+18.2% | $49.9M+4.4% | $46.5M+5.7% | $50.6M+21.0% | $45.1M+26.1% |
| R&D Expenses | $37.0M+68.0% | $28.4M-20.4% | $29.0M+46.2% | $22.6M+34.5% | $22.0M+32.0% | $35.7M+68.8% | $19.8M-18.5% | $16.8M+1.1% |
| SG&A Expenses | $71.8M+11.2% | $68.4M+36.5% | $63.0M+60.3% | $60.3M+60.4% | $64.6M+63.7% | $50.1M+66.5% | $39.3M+66.4% | $37.6M+51.7% |
| Operating Income | -$63.8M-65.7% | -$50.2M-22.4% | -$40.4M-292.6% | -$31.3M-184.4% | -$38.5M-279.5% | -$41.0M-344.3% | -$10.3M-44.9% | -$11.0M-83.5% |
| EBITDA | -$61.6M-68.7% | -$48.0M-22.8% | -$36.2M-344.8% | -$29.2M-223.6% | -$36.5M-346.1% | -$39.0M-456.9% | -$8.1M-37.0% | -$9.0M-66.8% |
| Income Tax | $129K+101.7% | $143K+101.8% | $103.2M+6610.1% | -$5.8M-530.9% | -$7.7M-669.5% | -$7.9M-1420.1% | -$1.6M-314.5% | -$920K-258.0% |
| Net Income | -$62.5M-129.8% | -$48.6M-64.7% | -$141.2M-2774.9% | -$22.6M-324.2% | -$27.2M-502.2% | -$29.5M-611.4% | -$4.9M-103.9% | -$5.3M-3986.1% |
| EPS (Basic) | -$1.04-126.1% | -$0.82-64.0% | -$2.39-2555.6% | -$0.38-322.2% | -$0.46-475.0% | -$0.50-614.3% | -$0.09-80.0% | -$0.09 |
| EPS (Diluted) | -$1.04-126.1% | -$0.82-64.0% | -$2.39-2555.6% | -$0.38-322.2% | -$0.46-475.0% | -$0.50-614.3% | -$0.09-80.0% | -$0.09 |
| Diluted Shares (Avg) | 60M+2.1% | 59M+1.6% | N/A | 59M+1.4% | 59M+1.3% | 59M+1.3% | N/A | 58M+1.2% |
Not reported in any period shown, so not listed: Interest Expense.
VNDA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $412.5M-34.0% | $433.5M-31.4% | $488.9M-25.5% | $601.1M-6.8% | $624.7M-4.1% | $631.9M-3.2% | $656.2M+1.2% | $645.1M+0.5% |
| Current Assets | $264.5M-33.0% | $293.2M-28.1% | $347.3M-20.9% | $367.5M-15.0% | $394.9M-10.1% | $407.9M-7.2% | $438.9M+1.4% | $432.4M-19.4% |
| Cash & Equivalents | $55.9M-31.0% | $54.0M-51.7% | $84.9M-17.1% | $70.0M-30.3% | $81.0M-21.3% | $111.8M-10.7% | $102.3M-24.7% | $100.5M-45.1% |
| Short-Term Investments | $114.1M-53.3% | $148.3M-35.3% | $179.0M-34.3% | $223.7M-18.9% | $244.6M-14.1% | $229.1M-14.8% | $272.3M+7.9% | $275.8M-10.1% |
| Inventory | $1.7M-22.6% | $1.7M-11.6% | $1.9M+7.3% | $2.0M+26.5% | $2.2M+47.7% | $1.9M+27.8% | $1.7M+27.2% | $1.6M+60.4% |
| Accounts Receivable | $59.7M+32.7% | $56.9M+27.5% | $54.6M+15.9% | $50.5M+18.2% | $45.0M+7.5% | $44.6M+21.5% | $47.1M+37.9% | $42.8M+46.1% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $192.3M+38.9% | $152.8M+26.8% | $161.8M+37.5% | $135.1M+30.1% | $138.4M+27.2% | $120.5M+10.9% | $117.7M+13.6% | $103.9M+5.5% |
| Current Liabilities | $164.0M+35.0% | $135.6M+30.5% | $145.2M+45.2% | $117.9M+32.3% | $121.5M+29.5% | $103.9M+11.3% | $100.0M+14.0% | $89.1M+5.0% |
| Non-Current Liabilities | $28.3M+66.9% | $17.2M+3.5% | $16.6M-6.1% | $17.3M+16.7% | $16.9M+12.4% | $16.6M+8.2% | $17.7M+11.6% | $14.8M+8.3% |
| Total Equity | $220.2M-54.7% | $280.8M-45.1% | $327.2M-39.2% | $466.0M-13.9% | $486.3M-10.4% | $511.4M-6.0% | $538.5M-1.2% | $541.2M-0.3% |
| Retained Earnings | -$505.8M-119.0% | -$443.3M-117.5% | -$394.8M-126.5% | -$253.6M-49.7% | -$231.0M-40.8% | -$203.8M-27.7% | -$174.3M-12.2% | -$169.4M-10.7% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
VNDA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$31.1M-103.7% | -$50.2M-51.5% | -$29.4M-1519.0% | -$31.6M-116.9% | -$15.3M-120.2% | -$33.1M-537.9% | -$1.8M+51.3% | -$14.6M-611.3% |
| Depreciation & Amortization | $2.3M+11.7% | $2.3M+14.0% | $2.1M+4.2% | $2.1M+4.4% | $2.0M+2.5% | $2.0M-10.8% | $2.0M+70.4% | $2.0M+239.1% |
| Stock-Based Compensation | $2.1M0.0% | $2.6M-13.7% | N/A | $2.1M-29.6% | $2.1M-29.5% | $3.0M-17.1% | N/A | $3.0M-5.3% |
| Capital Expenditures | $190K-36.5% | $221K-49.3% | $102K-52.3% | $161K0.0% | $299K+176.9% | $436K+6128.6% | $214K-15.4% | $161K+570.8% |
| Free Cash Flow | -$31.3M-101.0% | -$50.4M-50.2% | -$29.5M-1353.4% | -$31.8M-115.6% | -$15.6M-121.0% | -$33.6M-544.1% | -$2.0M+49.0% | -$14.7M-610.8% |
| Investing Cash Flow | $33.8M+321.4% | $20.2M-53.9% | $44.9M+1023.6% | $21.4M+77.2% | -$15.3M-0.1% | $43.9M+341.0% | $4.0M+109.1% | $12.1M-65.9% |
| Financing Cash Flow | -$856K-101.4% | -$776K+41.4% | -$640K-312.9% | -$517K | -$425K | -$1.3M | -$155K | $0 |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VNDA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.0%-1.8pp | 93.9%+0.9pp | 93.3%-1.8pp | 94.8%+0.1pp | 94.8%+0.2pp | 93.0%+0.2pp | 95.1%+2.8pp | 94.7%+2.5pp |
| Operating Margin | -126.3% | -97.1%-15.1pp | -70.5%-51.2pp | -55.6%-32.5pp | -73.2%-53.1pp | -82.0%-62.5pp | -19.3%-3.7pp | -23.1%-7.6pp |
| Net Margin | -123.7% | -93.9%-35.0pp | -246.8% | -40.2%-29.0pp | -51.7%-42.8pp | -58.9%-50.2pp | -9.2%-3.9pp | -11.2%-11.5pp |
| Return on Equity | -28.4%-22.8pp | -17.3%-11.5pp | -43.2%-42.2pp | -4.9%-3.9pp | -5.6%-4.8pp | -5.8%-5.0pp | -0.9%-0.5pp | -1.0%-1.0pp |
| Return on Assets | -15.2%-10.8pp | -11.2%-6.5pp | -28.9%-28.1pp | -3.8%-2.9pp | -4.3%-3.7pp | -4.7%-4.0pp | -0.8%-0.4pp | -0.8%-0.9pp |
| Current Ratio | 1.61-1.6x | 2.16-1.8x | 2.39-2.0x | 3.12-1.7x | 3.25-1.4x | 3.93-0.8x | 4.39-0.5x | 4.85-1.5x |
| Debt-to-Equity | 0.87+0.6x | 0.54+0.3x | 0.49+0.3x | 0.29+0.1x | 0.28+0.1x | 0.240.0x | 0.220.0x | 0.190.0x |
| Asset Turnover | 0.120.0x | 0.120.0x | 0.120.0x | 0.090.0x | 0.080.0x | 0.080.0x | 0.080.0x | 0.070.0x |
| FCF Margin | -61.9%-32.3pp | -97.5%-30.4pp | -51.6%-47.8pp | -56.5%-25.6pp | -29.6%-15.6pp | -67.1%-83.0pp | -3.8%+5.0pp | -30.9%-25.6pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. VNDA | FY2025 | $216.1M | -$220.5M | N/A | $279.9M | 35/100 |
| Neumora Therapeutics, Inc. NMRA | FY2025 | N/A | $236.9M | N/A | $93.9M | — |
| Omeros Corporation OMER | FY2025 | N/A | N/A | N/A | $1.3B | — |
| Tonix Pharmaceuticals Holding Corp. TNXP | FY2025 | $13.1M | -$124.0M | N/A | $152.8M | 69/100 |
| Candel Therapeutics, Inc. CADL | FY2025 | N/A | -$38.2M | N/A | $779.0M | — |
| Lexeo Therapeutics, Inc. LXEO | FY2025 | N/A | -$100.0M | N/A | $289.8M | — |
Where Vanda Pharmaceuticals Inc. Ranks
Frequently Asked Questions
What is Vanda Pharmaceuticals Inc.'s annual revenue?
Vanda Pharmaceuticals Inc. (VNDA) reported $216.1M in total revenue for fiscal year 2025. This represents a 8.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Vanda Pharmaceuticals Inc.'s revenue growing?
Vanda Pharmaceuticals Inc. (VNDA) revenue grew by 8.7% year-over-year, from $198.8M to $216.1M in fiscal year 2025.
Is Vanda Pharmaceuticals Inc. profitable?
No, Vanda Pharmaceuticals Inc. (VNDA) reported a net income of -$220.5M in fiscal year 2025.
What is Vanda Pharmaceuticals Inc.'s EBITDA?
Vanda Pharmaceuticals Inc. (VNDA) had EBITDA of -$140.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Vanda Pharmaceuticals Inc.'s gross margin?
Vanda Pharmaceuticals Inc. (VNDA) had a gross margin of 94.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Vanda Pharmaceuticals Inc.'s operating margin?
Vanda Pharmaceuticals Inc. (VNDA) had an operating margin of -70.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Vanda Pharmaceuticals Inc.'s return on equity (ROE)?
Vanda Pharmaceuticals Inc. (VNDA) has a return on equity of -67.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Vanda Pharmaceuticals Inc.'s free cash flow?
Vanda Pharmaceuticals Inc. (VNDA) recorded an outflow of $110.4M in free cash flow during fiscal year 2025. This represents a -579.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Vanda Pharmaceuticals Inc.'s operating cash flow?
Vanda Pharmaceuticals Inc. (VNDA) recorded an outflow of $109.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Vanda Pharmaceuticals Inc.'s total assets?
Vanda Pharmaceuticals Inc. (VNDA) had $488.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Vanda Pharmaceuticals Inc.'s capital expenditures?
Vanda Pharmaceuticals Inc. (VNDA) invested $998K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Vanda Pharmaceuticals Inc. spend on research and development?
Vanda Pharmaceuticals Inc. (VNDA) invested $109.3M in research and development during fiscal year 2025.
What is Vanda Pharmaceuticals Inc.'s current ratio?
Vanda Pharmaceuticals Inc. (VNDA) had a current ratio of 2.39 as of fiscal year 2025, which is generally considered healthy.
What is Vanda Pharmaceuticals Inc.'s debt-to-equity ratio?
Vanda Pharmaceuticals Inc. (VNDA) had a debt-to-equity ratio of 0.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Vanda Pharmaceuticals Inc.'s return on assets (ROA)?
Vanda Pharmaceuticals Inc. (VNDA) had a return on assets of -45.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Vanda Pharmaceuticals Inc.'s P/E ratio?
Vanda Pharmaceuticals Inc. (VNDA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $279.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Vanda Pharmaceuticals Inc.'s price-to-sales ratio?
Vanda Pharmaceuticals Inc. (VNDA) trades at 1.3x sales, its market capitalization divided by revenue of $215.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $279.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Vanda Pharmaceuticals Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Vanda Pharmaceuticals Inc. (VNDA) held $263.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $109.4M over that year. Dividing the one by the other, the reported balance equals about 29 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Vanda Pharmaceuticals Inc.'s Altman Z-Score?
Vanda Pharmaceuticals Inc. (VNDA) has an Altman Z-Score of -0.17, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Vanda Pharmaceuticals Inc.'s Piotroski F-Score?
Vanda Pharmaceuticals Inc. (VNDA) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Vanda Pharmaceuticals Inc.'s earnings high quality?
Vanda Pharmaceuticals Inc. (VNDA) reported a net loss of $220.5M while operations used $109.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Vanda Pharmaceuticals Inc.?
Vanda Pharmaceuticals Inc. (VNDA) scores 35 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.